Sinopia Biosciences Awarded Phase II SBIR to Focus on Drug Side Effects

Sinopia Biosciences was awarded a Phase II Small Business Innovation Research (SBIR) Grant from the National Institute of General Medical Sciences (NIGMS) branch of the National Institutes of Health (NIH) to further support research and commercialization of Sinopia’s technology in predicting, preventing, and treating adverse drug reactions, more commonly known as drug side effects. The grant is entitled “Developing a systems biology platform for predicting, preventing, and treating drug side effects“. The award for approximately $1.5 million will go to further expanding Sinopia’s underlying technology to study the efficacy and safety of therapeutics at a comprehensive biomolecular level. With the successes in the Phase I portion of this SBIR and the development of a program for Parkinson’s Disease, this grant will expand Sinopia’s research into other therapeutic areas including psychiatry and oncology.